180 related articles for article (PubMed ID: 34339834)
21. Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
Jamil MO; Mehta A
Expert Rev Hematol; 2016 May; 9(5):471-7. PubMed ID: 26808217
[TBL] [Abstract][Full Text] [Related]
22. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature.
Kerbauy FR; Colleoni GW; Saad ST; Regis Silva MR; Correa Alves A; Aguiar KC; Albuquerque DM; Kobarg J; Seixas MT; Kerbauy J
Leuk Lymphoma; 2004 Oct; 45(10):2071-8. PubMed ID: 15370252
[TBL] [Abstract][Full Text] [Related]
23. Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell Lymphoma by Targeted Gene Sequencing.
Sharma A; Das A; Bal A; Srinivasan R; Malhotra P; Prakash G; Kumar R
Cytogenet Genome Res; 2023; 163(5-6):279-289. PubMed ID: 38071955
[TBL] [Abstract][Full Text] [Related]
24. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
26. TP53 mutation and survival in aggressive B cell lymphoma.
Zenz T; Kreuz M; Fuge M; Klapper W; Horn H; Staiger AM; Winter D; Helfrich H; Huellein J; Hansmann ML; Stein H; Feller A; Möller P; Schmitz N; Trümper L; Loeffler M; Siebert R; Rosenwald A; Ott G; Pfreundschuh M; Stilgenbauer S;
Int J Cancer; 2017 Oct; 141(7):1381-1388. PubMed ID: 28614910
[TBL] [Abstract][Full Text] [Related]
27. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].
Miyazaki K
Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444
[TBL] [Abstract][Full Text] [Related]
28. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
29. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
[TBL] [Abstract][Full Text] [Related]
30. Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol.
Pillon M; Mussolin L; Carraro E; Conter V; Aricò M; Vinti L; Garaventa A; Piglione M; Buffardi S; Sala A; Santoro N; Lo Nigro L; Mura R; Tondo A; Casale F; Farruggia P; Pierani P; Cesaro S; d'Amore ES; Basso G
Br J Haematol; 2016 Nov; 175(3):467-475. PubMed ID: 27392319
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
32. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
33. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
34. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
35. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.
Park HY; Lee SB; Yoo HY; Kim SJ; Kim WS; Kim JI; Ko YH
Oncotarget; 2016 Dec; 7(52):86433-86445. PubMed ID: 27835906
[TBL] [Abstract][Full Text] [Related]
36. Improving outcomes for patients with diffuse large B-cell lymphoma.
Flowers CR; Sinha R; Vose JM
CA Cancer J Clin; 2010; 60(6):393-408. PubMed ID: 21030533
[TBL] [Abstract][Full Text] [Related]
37. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Karube K; Enjuanes A; Dlouhy I; Jares P; Martin-Garcia D; Nadeu F; Ordóñez GR; Rovira J; Clot G; Royo C; Navarro A; Gonzalez-Farre B; Vaghefi A; Castellano G; Rubio-Perez C; Tamborero D; Briones J; Salar A; Sancho JM; Mercadal S; Gonzalez-Barca E; Escoda L; Miyoshi H; Ohshima K; Miyawaki K; Kato K; Akashi K; Mozos A; Colomo L; Alcoceba M; Valera A; Carrió A; Costa D; Lopez-Bigas N; Schmitz R; Staudt LM; Salaverria I; López-Guillermo A; Campo E
Leukemia; 2018 Mar; 32(3):675-684. PubMed ID: 28804123
[TBL] [Abstract][Full Text] [Related]
38. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
39. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
40. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]